Transparency in clinical trials is continually changing, and to stay on top of the news, TrialAssure brings a weekly round-up of some of the key stories surrounding disclosures in clinical trials. This week’s stories are as follows:
State of the industry report – Outsourcing-Pharma
Outsourcing-Pharma released a State of the Industry report that sheds light on the global pharmaceutical industry. One of the key findings in the report showed that more than half of survey respondents believe that industry initiatives will lead to greater transparency. The report points to a new pilot program launched earlier this year by the FDA to increase transparency.
Read the report here.
Transparency is a concern in China – STAT
China, as the second largest pharmaceutical market in the world, is struggling with clinical trial transparency and data reliability. In the past few years, fabricated data has been a real concern for China’s Food and Drug Administration (CFDA). This discovery led to 90 percent of application to the CFDA being rejected. The CFDA has made steps since then to increase transparency.
Read the full article here.
Blockchain to improve transparency – Coin Announcer
Blockchain technology may speed the drug development process, bringing treatments to patients 3–5 years sooner than the traditional method. This in part is due to blockchain’s ability to ease the tension in sharing data, while adequately protecting patient privacy. Researchers have struggled to effectively aggregate and use the vast amounts of data that have been collected over the years to inform decisions. Blockchain is said to allow the industry to use this data more fully, improving transparency while inherently maintaining trust and data privacy.
Read the full article here.
